Transcenta Holding Limited 創勝集團醫藥有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 有關就解決截至2024年12月31日止年度的 年度報告內無法表示意見所採取措施及行動的最新進展 創勝集團醫藥有限公司（「本公司」，連同其附屬公司統稱為「本集團」）董事會 （「董事會」）謹此向股東及潛在投資者提供有關就解決其截至2024年12月31日止年 度的年度報告（「年報」）內所載的無法表示意見（「無法表示意見」）所採取措施及 行動的執行進度的最新進展。本公告所用但並無另行界定的詞彙應與年報中所賦 予該等詞彙的涵義相同。 自於2025年4月22日刊發年報、於2025年7月11日刊發最新進展公告、於2025年8 月27日刊發中期業績公告及於2025年10月22日刊發後續更新公告以來，本集團就 最初於年報內所載的九項關鍵措施持續取得切實進展，該等措施旨在增強其財務 狀況、提升流動性並解決無法表示意見。有關執行進度、狀況及預期成果的 ...

Group 1 - OTC Markets Group Inc. announced that Bora Pharmaceuticals Co., Ltd. has been added to the OTCQX® Best Market eligible trading list, allowing its shares to trade under the ticker "BORAY" [1] - The inclusion in the OTCQX market enables Bora Pharmaceuticals to efficiently expand its financing channels in the U.S. capital market while maintaining its primary listing in Taiwan [1] - OTCQX requires companies to meet high financial standards and adhere to best corporate governance practices, ensuring compliance with applicable securities laws [1] Group 2 - Jason Paltrowitz, Executive Vice President of OTC Markets Group, expressed that Bora Pharmaceuticals is the first Taiwanese issuer to join the OTCQX market, enhancing its visibility among U.S. investors and showcasing OTCQX's global influence [2] - Bobby Sheng, Chairman of Bora Group, highlighted that this milestone allows for cross-market trading in the U.S. through the Level 1 ADR program, which broadens investment channels for U.S. investors while maintaining liquidity for shareholders [3] - Bora Pharmaceuticals aims to become a truly global enterprise, with over 95% of its revenue coming from markets outside Taiwan, and emphasizes the importance of liquidity, trust, and long-term value creation [3] Group 3 - Bora Pharmaceuticals, established in 2007, is a leading pharmaceutical services company focused on integrating contract research, development, and manufacturing (CDMO) with commercial expertise to accelerate product development and meet global patient needs [4] - The company is actively expanding its R&D and sales infrastructure, focusing on niche and rare disease markets to improve patient quality of life [4] - Bora is committed to innovation and sustainable growth through investments in talent, infrastructure, and biopharmaceutical business expansion, setting new standards in the pharmaceutical and CDMO industries [4]